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Abstract
Background:  We assessed the nm23-H1 gene product expression and its relationship with
lymphatic and blood vessel invasion in patients with esophageal squamous cell carcinoma.
Methods:  Formalin-fixed and paraffin-embedded tissue sections from 45 patients who were
treated surgically were used in this study. Pathologists graded lymphatic and blood vessel invasion
in each of the tissue samples. Expression of nm23-Hl gene product was determined using a specific
monoclonal antibody.
Results:  Expression of nm23-H1 gene product was present in 17 (37.8%) cases. We found an
inverse correlation between nm23-H1 gene product expression and lymphatic vessel invasion,
whereas no correlation between nm23-H1 gene product expression and blood vessel invasion.
Overall survival rate was not different between nm23-H1 gene product positive and negative
patients (p = 0.21). However, reduced expression of nm23-H1 gene product was associated with
shorter overall survival in patients with involved lymph nodes (p < 0.05), but not in patients without
involved lymph nodes (p = 0.87).
Conclusions:  In patients with esophageal squamous cell carcinoma, there appears to be an
inverse relationship between nm23-H1 gene product expression and lymphatic vessel invasion.
Furthermore, nm23-H1 gene product expression might be a prognostic marker in patients with
involved lymph nodes. Our data does not demonstrate any correlation between nm23-H1 gene
product expression and blood vessel invasion.
Background
Expression of nm23-H1 gene product is thought to play a
specific biological role in suppressing tumor metastasis
[1,2]. A number of studies of human malignant tumors
including breast [3–5], gastric [6,7], colorectal [8,9],
hepatocellular [10], and ovarian [11] carcinomas have
demonstrated a correlation between reduced expression
of nm23 mRNA or its gene product and increased metas-
tasis, resulting in poorer prognosis. With regard to lung
cancer, however, previous studies have shown that nm23
gene product expression is unrelated to patient survival
[12]. The reasons for these conflicting results remain un-
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clear. Although very little attention has been given to the
role of nm23-H1 gene product in esophageal squamous
cell carcinoma, two studies report on the relationship be-
tween nm23-H1 expression and patient survival [13,14].
It is general knowledge that vessel invasion is the first
and necessary step at the outset of the metastatic cas-
cade. What remains to be seen, however, is whether
nm23-H1 gene product expression is associated with
lymphatic or blood vessel invasion in patients with es-
ophageal squamous cell carcinoma. The present study
examines this question.
Materials and methods
Patients and tissue samples
Forty-five randomly selected patients (39 men, 6 wom-
en) with primary esophageal squamous cell carcinoma
who were treated surgically at Miyazaki Medical College
were included in this study. TNM staging was accom-
plished in all patients [15]. Surgically resected tissue
samples previously fixed in formalin and embedded in
paraffin were used in this study. Following the Guide-
lines for the Clinical and Pathologic Studies on Carcino-
ma of the Esophagus (Japanese Society for Esophageal
Diseases, 1999), pathologists graded lymphatic and
blood vessel invasion in each of the tissue samples. Brief-
ly, lymphatic vessel invasion was graded according to the
following: ly0: none; ly1: mild; ly2: moderate; and ly3:
severe. Blood vessel invasion was also graded as follows:
v0: none; v1: mild; v2: moderate; and v3: severe.
Immunohistochemical studies
The specific monoclonal antibody against nm23-H1 gene
product (Novocastra Laboratories, Newcastle, UK) was
used to detect gene product expression. Before staining,
serial 4 µ m-thick sections were deparaffinized in three
changes of lemosol and rehydrated through a descending
series of ethanol. These sections were then immersed in
0.6% H2O2 in methanol for 20 minutes at room temper-
ature to block endogenous peroxidase activity. After
blocking nonspecific protein bindings by an overnight
incubation with Block Ace (Dainippon Inc., Osaka, Ja-
pan), the sections were incubated with primary antibod-
ies (1:200) at 4° C overnight. Subsequently, sections were
incubated with the secondary antiserum (1:500) for 1
hour, followed by an incubation with peroxidase antiper-
oxidase (PAP) complex for 30 minutes at room tempera-
ture. The sections were visualized using a
Diaminobenzidine/Metal Concentration (10X) and Sta-
ble Peroxide Substrate Buffer (1x) system (Pierce, Rock-
ford, IL, USA). The sections were then washed with
water and counterstained with hematoxylin. Immuno-
histochemical results were assessed semiquantitatively
by two authors, taking into account the percentage of
nm23-H1 protein positive cancer cells within the maxi-
mum cut-surface specimen of the tumor tissue. Patients
with greater than 50% of cancer cells staining more in-
tensely than stromal cells were considered positive for
nm23-H1 gene product expression.
Statistical analysis
Data was analyzed using the X 2 test with Yates' correla-
tion. Survival curves were plotted according to the Kap-
lan-Meier method, and the prognostic significance was
evaluated by the generalized Wilcoxon test. A p value less
than 0.05 was considered significant.
Results
Expression of nm23-H1 gene product was present in 17
(37.8%) cases and appeared diffusely throughout the cy-
toplasm of the cancer cells (Fig. 1). In the majority of
nm23-H1 gene product positive cancers, most of tumor
cells contained a homologous cytoplasmic pattern for
nm23-H1 gene product. Table 1 shows the relationship
between nm23-H1 gene product expression and clinical
characteristics. Expression of nm23-H1 gene product
was not correlated with these clinical factors. Lymph
node metastasis in positive nm23-H1 gene product cases
was 9/17 (52.9%); in negative cases, 13/28 (46.4%).
There was no significant correlation between nm23-H1
gene product expression and lymph node metastasis.
Lymphatic vessel invasion gradings included: 1 ly0, 18
ly1, 24 ly2, and 2 ly3. Since the ly0 and ly3 numbers were
low, lymphatic vessel invasion was classified into two
groups: ly0+ly1 and ly2+ly3. Lymph node metastasis in
the ly0+ly1 and ly2+ly3 groups was 6/19 (31.6%) and 17/
26 (65.4%), respectively. These numbers indicate a rela-
tionship between lymphatic vessel invasion and lymph
node metastasis (p < 0.05).
Table 2 shows the relationship between nm23-H1 gene
product expression and lymphatic vessel invasion, and
blood vessel invasion. Expression of nm23-H1 gene
product in the ly0+ly1 and ly2+ly3 groups was 12/19
(63.2%) and 5/26 (19.2%), respectively, while numbers
for the nm23-H1 negative cases were 7/19 (36.8%) and
21/26 (80.8%), respectively, indicating an inverse rela-
tionship between nm23-H1 gene product expression and
lymphatic vessel invasion (p < 0.01). Blood vessel inva-
sion gradings included 14 v0, 27 v1, 4 v2, and no v3 cases.
Of these numbers, expression of nm23-H1 gene product
was present in 7 v0, 7 v1, and 3 v2 cases. In nm23-H1
gene product negative patients, there were 7 v0, 20 v1,
and 1 v2 cases. As is apparent from these numbers, we
found no correlation between nm23-H1 gene product ex-
pression and blood vessel invasion.BMC Cancer (2001) 1:3 http://www.biomedcentral.com/1471-2407/1/3
The number of patients who underwent pre- or post-op-
erative radiotherapy in nm23-H1 positive and negative
groups was 9/17 (52.9%) and 13/28 (53.6%), respective-
ly, and there was no difference between these groups. In
the present series, no correlation between 5-year survival
rates and nm23-H1 gene product expression was found
(22.9% vs. 23.8%, p = 0.21). However, in patients with
involved lymph nodes, 5-year survival rates of nm23-H1
gene product positive and negative group was 16.7% and
7.7%, respectively. As shown Fig. 2, reduced expression
of nm23-H1 gene product was associated with shorter
overall survival in patients with involved lymph nodes (p
< 0.05). In patients without involved lymph nodes, there
was no significant difference in patients' survival be-
tween these groups (p = 0.87).
Discussion
Our study revealed nm23-H1 gene product expression in
17 (37.8%) of 45 patients with esophageal squamous cell
carcinoma. Other researchers have reported similar
findings in patients with this type of cancer. Patel et al.
[13] demonstrated positive nm23 staining in 13 (29%) of
45 patients with T3-4N1M0 esophageal carcinoma, and
Iizuka et al. [14] reported positive nm23 staining in 23
(46%) of 50 patients. Two possible explanations for the
wide range of percentages in these studies include differ-
ences in the specificity of the antibody used or differenc-
es in the method for evaluating nm23-H1 gene product
staining.
Earlier studies have reported a clear correlation between
lymphatic vessel invasion and regional lymph node me-
tastases in esophageal squamous cell carcinoma [16,17].
Our data also suggests an association between lymphatic
vessel invasion and lymph node metastasis.
Although in certain other cancers [3,6,9,18], nm23-H1
gene product expression appears to be related to lymph
node metastasis, our study of patients with esophageal
squamous cell carcinoma showed no correlation between
nm23-H1 gene product expression and lymph node me-
tastasis, findings compatible with those of Iizuka et al.
[14]. We did observe, however, an inverse correlation be-
tween nm23-H1 gene product expression and lymphatic
Table 1: Clinical characteristics
nm23(-) nm23(+) Total p-value
Gender NS
Male 24 15 39
F e m a l e 426
Age NS
<60 5 7 12
> 6 0 2 31 03 3
Location NS
Upper thoracic 5 2 7
Mid thoracic 12 11 23
Lower thoracic 11 4 15
PT NS
pT1 3 7 10
p T 2 527
pT3 20 8 28
p T 4 000
PN NS
pN0 15 8 23
pN1 13 9 22
Stage NS
I 369
II 14 5 19
III 7 4 11
I V 426
Differentiation NS
W e l l 437
Moderate 18 10 28
Poor 6 4 10
NS: not significantBMC Cancer (2001) 1:3 http://www.biomedcentral.com/1471-2407/1/3
vessel invasion. These results suggest that expression of
nm23-H1 gene product may not have implications for
lymph node metastasis but may play a part in local inva-
sion. However, our results and Iizuka et al. [14] also
showed that reduced expression of nm23-H1 in esopha-
geal squamous cell carcinoma is associated with a short-
er overall survival rate in patients with lymph node
involvement, but not in patients without lymph node in-
volvement. Moreover, lymphatic vessel invasion is the
first and necessary step at the outset of the metastatic
cascade. It has been demonstrated that lymphatic vessel
invasion is an independent prognostic factor in esopha-
geal squamous cell carcinoma [16]. Thus, taken together,
one must consider the possibility that, in esophageal sq-
uamous cell carcinoma, nm23-H1 gene product plays a
role in the metastatic process following lymphatic
spread. Further studies are required to determine the ex-
act role of nm23-H1 gene product in the lymphatic
spread of cancer cells in this type of carcinoma.
Figure 1
Positive staining for nm23-H1 gene product in esophageal squamous cell carcinoma (original magnification ×  100).
Table 2: Relationship between nm23-H1 gene product expression 
and lymphatic and blood vessel invasion.
nm23-H1 
(-)
nm23-H1 
(+)
p-value
Lymphatic vessel invasion p < 0.01
ly0+ly1 7 12
ly2+ly3 21 5
Blood vessel invasion NS
v0 7 7
v1 20 7
v2 1 3
v3 0 0
NS: not significantBMC Cancer (2001) 1:3 http://www.biomedcentral.com/1471-2407/1/3
Furthermore, additional studies are needed to clarify the
exact relationship between nm23-H1 gene product ex-
pression and blood vessel invasion. Among breast cancer
studies, Dueñas et al. [19] reported a correlation between
nm23-H1 expression and blood vessel invasion, while
Royds et al. [20] found no such correlation. In colorectal
cancer, Yamaguchi et al. and Royds et al. found no signif-
icant correlation between nm23-H1 expression and
blood vessel invasion [10,21]. In gastric cancer, interest-
ingly, Müller et al. reported a positive correlation be-
tween nm23-H1 expression and blood vessel invasion
[8]. Our present study on esophageal squamous cell car-
cinoma found no correlation between nm23-H1 gene
product expression and blood vessel invasion. To the
best of our knowledge, there are no previous studies on
the relationship between nm23-H1 expression and dis-
tant metastasis in esophageal squamous cell carcinoma
although Sarbia et al. [16] demonstrated a clear correla-
tion between blood vessel invasion and distant metastas-
es. Our data suggests that, in esophageal squamous cell
carcinoma, nm23-H1 gene product expression may not
be associated with distant metastasis.
Cohn et al. [22] suggested that, in colorectal cancer, allel-
ic deletion of the nm23-H1 gene has been shown to have
possible antimetastatic functions. Although we did not
determine allelic deletion in the presence of nm23-H1
gene product expression in our study, the possibility re-
mains that changes in the nm23-H1 locus have an an-
timetastatic function in esophageal squamous cell
carcinoma as well. Metastasis is a cascade of linked se-
quential steps involving multiple host- tumor interac-
tions. To form a metastatic focus, a tumor cell or group of
cells is required to leave the primary tumor, invade local
tissues and basement membranes, enter the circulation,
avoid host immunological responses, attach to a distant
vascular bed, extravasate into the interstitium of the tar-
get organ, and colonize to form a second tumor [23]. Fur-
ther studies are required to clarify the specific role of
nm23-H1 gene product in this multi-step metastatic
process.
In conclusion, we found an inverse correlation between
nm23-H1 gene product expression and lymphatic vessel
invasion but found no correlation between nm23-H1
gene product and blood vessel invasion in patients with
esophageal squamous cell carcinoma. Furthermore,
nm23-H1 gene product expression might be a prognostic
marker in patients with involved lymph nodes.
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